# Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

> **NCT05164471** · PHASE1,PHASE2 · TERMINATED · sponsor: **Spur Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **GENETIC:** verbrinacogene setparvovec

## Key facts

- **NCT ID:** NCT05164471
- **Lead sponsor:** Spur Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-06
- **Primary completion:** 2023-05-31
- **Final completion:** 2023-05-31
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Freeline has decided to pause development of FLT180a for business priorities
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05164471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05164471, "Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05164471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*